Lv5
1150 积分 2022-03-23 加入
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
7天前
已完结
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 stud
8天前
已完结
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development
8天前
已完结
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib
13天前
已完结
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma
16天前
已完结
. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
16天前
已完结
Improved overall survival in melanoma with combined dabrafenib and trametinib
16天前
已完结
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 tria
18天前
已完结
Sunitinib therapy for melanoma patients with KIT mutations
18天前
已完结
BRAF fusions identified in melanomas have variable treatment responses and phenotypes
19天前
已完结
皖公网安备34019202002308
